Valuation: Whitehawk Therapeutics, Inc.

Market Cap 239M 209M 197M 179M 335M 22.98B 337M 2.36B 911M 11.68B 899M 879M 37.58B P/E 2026 *
-4.61x
P/E 2027 * -4.77x
Enterprise Value 239M 209M 197M 179M 335M 22.98B 337M 2.36B 911M 11.68B 899M 879M 37.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87.37%
Yield 2026 *
-
Yield 2027 * -
1 day+2.94%
1 week+2.19%
Current month-7.49%
1 month-13.76%
3 months-4.98%
6 months+16.99%
Current year+73.55%
1 week 3.96
Extreme 3.96
4.26
1 month 3.96
Extreme 3.96
5.1
Current year 2.36
Extreme 2.36
5.5
1 year 1.82
Extreme 1.82
5.5
3 years 1.21
Extreme 1.21
5.7
5 years 1.21
Extreme 1.21
32.99
10 years 1.21
Extreme 1.21
32.99
Manager TitleAgeSince
Chief Executive Officer 55 2023-10-01
Chief Executive Officer 55 2023-03-02
Chief Tech/Sci/R&D Officer 69 2025-11-30
Director TitleAgeSince
Chairman 61 2022-12-31
Chairman 55 2017-02-28
Director/Board Member 54 2021-08-25
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Chief Executive Officer

387,914 0.8231%
9/15/26 Free

Chief Technology Officer

162,500 0.3448%
9/15/26 Free

Chief Technology Officer

183,266 0.3889%
Change 5-day change 1-year change 3-year change Capi.($)
+2.94%+2.19%+118.75%-21.93% 239M
-0.58%+0.43%+32.58%-6.20% 78.37B
-2.55%+6.99%+510.30%+44.31% 61.5B
-1.11%+5.08%-11.48%-33.39% 59.78B
+0.14%-1.20%-11.21%+24.73% 46.53B
-0.24%+1.22%+2.36%+154.40% 45.5B
-1.62%-0.76%+51.23%-16.04% 31.84B
-1.81%+3.16%+44.82%+106.78% 25.4B
+0.47%+3.26%+4.94%+144.25% 21.43B
+0.27%+1.96%+59.19%+106.18% 15.77B
Average -0.41%+2.20%+80.15%+50.31% 38.64B
Weighted average by Cap. -0.92%+2.35%+94.92%+39.81%

Financials

2026 *2027 *
Net sales - -
Net income -74.98M -65.38M -61.74M -56.06M -105M -7.19B -105M -740M -285M -3.66B -282M -275M -11.77B -85.12M -74.23M -70.09M -63.65M -119M -8.17B -120M -840M -324M -4.15B -320M -313M -13.36B
Net Debt - -
Logo Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Employees
32
Date Price Change Volume
26-09-18 US$4.200 +2.94% 1,972,038
26-09-17 US$4.080 +0.99% 130,073
26-09-16 US$4.040 -1.22% 170,644
26-09-15 US$4.090 +0.49% 142,334
26-09-14 US$4.070 -0.97% 166,030
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.200USD
Average target price
7.500USD
Spread / Average Target
+78.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. WHWK Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!